September 11th 2025
Capvaxive was superior to PPSV23 for each of the 9 serotypes unique to Capvaxive and non inferior to PPSV23 for the 12 shared serotypes.
Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons
May 9th 2025"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.